Matricelf Ltd. (TASE: MTLF) is a preclinical-stage biotechnology company advancing the frontiers of personalized regenerative medicine. Leveraging a proprietary autologous platform, Matricelf engineers functional 3D neural implants using induced pluripotent stem cells (iPSCs) and extracellular matrix derived from each patient’s own tissue.
The company’s lead program targets spinal cord injury (SCI), a devastating condition with no curative therapy and an annual economic burden exceeding $40 billion in the U.S. Preclinical studies in FDA-accepted animal models have shown compelling safety and functional recovery, paving the way for a First-in-Human clinical trial planned for 2026.
Matricelf’s pipeline also includes stroke and traumatic brain injury, with early-stage research exploring additional indications in cardiovascular and retinal diseases. With a robust IP portfolio, scalable manufacturing capabilities, and a clear regulatory strategy, Matricelf is building the foundation to become a global leader in next-generation autologous therapies.
